Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Ripretinib |
Trade Name | Qinlock |
Synonyms | DCC-2618|DCC2618 |
Drug Descriptions |
Qinlock (ripretinib) is a dual inhibitor of KIT and PDGFRa, resulting in growth inhibition and anti-tumor effects (PMID: 29439183, PMID: 31085175, PMID: 31201392). Qinlock (ripretinib) is FDA approved for use in patients with advanced gastrointestinal stromal tumor who received 3 or more prior kinase inhibitor therapies (FDA.gov) |
DrugClasses | KIT Inhibitor 57 PDGFR-alpha Inhibitor 9 |
CAS Registry Number | 1442472-39-0 |
NCIT ID | C124067 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Binimetinib + Ripretinib | Binimetinib Ripretinib | 0 | 1 |
DCC-3116 + Ripretinib | DCC-3116 Ripretinib | 0 | 1 |
Repaglinide + Ripretinib | Repaglinide Ripretinib | 0 | 1 |
Ripretinib | Ripretinib | 79 | 4 |
Ripretinib + Sunitinib | Ripretinib Sunitinib | 5 | 0 |
Ripretinib + Trametinib | Ripretinib Trametinib | 0 | 0 |